Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination

References

• Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010; 28:3531-40; PMID:20547994; http://dx.doi.org/10.1200/JCO.2009.27.4787
   PubMed Web of Science ®Google Scholar
• Johnson DH, Schiller JH, Bunn PA. Recent clinical advances in lung cancer management. J Clin Oncol 2014; 32:973-82; PMID:24567433; http://dx.doi.org/10.1200/JCO.2013.53.1228
   PubMed Web of Science ®Google Scholar
• Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371:1039-49; PMID:25207767; http://dx.doi.org/10.1056/NEJMra1404198
   PubMed Web of Science ®Google Scholar
• Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer 2010; 46:1514-9; PMID:20413296; http://dx.doi.org/10.1016/j.ejca.2010.03.013
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/nature10673
   PubMed Web of Science ®Google Scholar
• Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29:4828-36; PMID:22042955; http://dx.doi.org/10.1200/JCO.2011.38.0899
   PubMed Web of Science ®Google Scholar
• Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599-613; PMID:22395641; http://dx.doi.org/10.1093/jnci/djs033
   PubMed Web of Science ®Google Scholar
• Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother 2011; 60:433-42; PMID:21221967; http://dx.doi.org/10.1007/s00262-010-0960-8
   PubMed Web of Science ®Google Scholar
• Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102:1388-97; PMID:20826737; http://dx.doi.org/10.1093/jnci/djq310
   PubMed Web of Science ®Google Scholar
• Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006; 97:970-6; PMID:16984371; http://dx.doi.org/10.1111/j.1349-7006.2006.00272.x
   PubMed Web of Science ®Google Scholar
• Sasada T, Yamada A, Noguchi M, Itoh K. Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem 2014; 21:2332-45; PMID:24524766; http://dx.doi.org/10.2174/0929867321666140205132936
   PubMed Web of Science ®Google Scholar
• Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, Sawamura Y, Kurisu K, Mineta T, Yamada A, et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011; 29:337-44; PMID:21149665; http://dx.doi.org/10.1200/JCO.2010.29.7499
   PubMed Web of Science ®Google Scholar
• Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59:1001-9; PMID:20146063; http://dx.doi.org/10.1007/s00262-010-0822-4
   PubMed Web of Science ®Google Scholar
• Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2012; 3:463-9; PMID:22969912
   PubMed Web of Science ®Google Scholar
• Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu K, et al. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol 2012; 40:1492-500; PMID:22307435
   PubMed Web of Science ®Google Scholar
• Yutani S, Komatsu N, Yoshitomi M, Matsueda S, Yonemoto K, Mine T, Noguchi M, Ishihara Y, Yamada A, Itoh K, et al. A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. Oncol Rep 2013; 30:1094-100; PMID:23784011
   PubMed Web of Science ®Google Scholar
• Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, Yamada A, Doi A, Suekane S, Moriya F, et al. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer 2012; 118:3208-21; PMID:22071976; http://dx.doi.org/10.1002/cncr.26636
   PubMed Web of Science ®Google Scholar
• Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH. Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118:499-509; PMID:21531979; http://dx.doi.org/10.1182/blood-2011-01-325266
   PubMed Web of Science ®Google Scholar
• López MN, Pereda C, Segal G, Muñoz L, Aguilera R, González FE, Escobar A, Ginesta A, Reyes D, González R, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor β-expressing T cells. J Clin Oncol 2009; 27:945-52; PMID:19139436; http://dx.doi.org/10.1200/JCO.2008.18.0794
   PubMed Web of Science ®Google Scholar
• Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2011; 10:1266-79; http://dx.doi.org/10.4161/cbt.10.12.13448
   Web of Science ®Google Scholar
• Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, Kakeji Y, Sugimachi K. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 1997; 17:2253-8; PMID:9216697
   PubMed Web of Science ®Google Scholar
• Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, Baba M, Shiba M. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999; 5:149-53; PMID:9918213
   PubMed Web of Science ®Google Scholar
• Tutton MG, George ML, Eccles SA, Burton S, Swift RI, Abulafi AM. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 2003; 107:541-50; PMID:14520690; http://dx.doi.org/10.1002/ijc.11436
   PubMed Web of Science ®Google Scholar
• Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007; 26:717-24; PMID:17717634; http://dx.doi.org/10.1007/s10555-007-9089-4
   PubMed Web of Science ®Google Scholar
• Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin-Colonna F, Lacerda K, Karadimou A, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30:83-95; PMID:21249423; http://dx.doi.org/10.1007/s10555-011-9281-4
   PubMed Web of Science ®Google Scholar
• Farina AR, Mackay AR. Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression. Cancers (Basel) 2014; 6:240-96; PMID:24473089; http://dx.doi.org/10.3390/cancers6010240
   PubMed Web of Science ®Google Scholar
• Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6:409-21; PMID:15488763; http://dx.doi.org/10.1016/j.ccr.2004.08.031
   PubMed Web of Science ®Google Scholar
• Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5:641-54; PMID:16056256; http://dx.doi.org/10.1038/nri1668
   PubMed Web of Science ®Google Scholar
• Kisand K, Kerna I, Kumm J, Jonsson H, Tamm A. Impact of cryopreservation on serum concentration of matrix metalloproteinases (MMP)-7, TIMP-1, vascular growth factors (VEGF) and VEGF-R2 in Biobank samples. Clin Chem Lab Med 2011 Feb; 49(2):229-35
   PubMed Web of Science ®Google Scholar